Phase 2 Melanoma Trial, Recruiting NCT06223659 Sponsor: Ohio State University Comprehensive Cancer Center Condition: Melanoma
Back to Melanoma

Phase 2 Melanoma Trial, Recruiting

NCT06223659
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are biologically male or female, aged 18 to 99 years
  • People who have been diagnosed with a skin cancer (such as cutaneous melanoma, Merkel cell carcinoma, squamous cell carcinoma, or another type of skin cancer) confirmed by a tissue sample, and for whom a doctor has recommended a procedure to check nearby lymph nodes (called lymphoscintigraphy and sentinel lymph node biopsy)

Who may not be able to join:

  • People with a known allergy or bad reaction to numbing creams or medicines such as EMLA cream, lidocaine, prilocaine, or similar local anaesthetics
  • People with a history of allergy to adhesive materials (such as bandages or medical tape)
  • People for whom the use of a radioactive tracer injection (Tc99) used during the lymph node mapping procedure is medically unsuitable (confirm with trial site)
  • People who are currently incarcerated
  • People who are not able to give their own consent independently
  • People whose lymph node mapping procedure site is in a mucosal or genital area
  • People who are pregnant
  • People who have chronic pain listed as an existing diagnosis in their own declaration or in their Ohio State University medical records
  • People who have pain lasting 3 months or longer (as defined by the US Centers for Disease Control and Prevention), unless their pain is from a stable condition such as nerve damage, fibromyalgia, arthritis, or cancer-related pain and they do not use narcotic (opioid) pain medicines
  • People who have used narcotic (opioid) pain medicines at any point in the 7 days before the procedure

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Carlo M Contreras, MD, Ohio State University Comprehensive Cancer Center

Phone: 800-293-5066

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Ohio State University Comprehensive Cancer Center
Registry
ClinicalTrials.gov
Start date
19 December 2023
Est. completion
31 October 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pain score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov